Effects of Isoflavone Supplementation on the Response to Medroxyprogesterone in Premenopausal Women with Nonatypical Endometrial Hyperplasia: A Randomized, Double-Blind, Placebo-Controlled Trial

Table 2

Endometrial histology and serum estradiol levels at the baseline and after the 3-month intervention period in women with nonatypical endometrial hyperplasia that received either isoflavone or the placebo.

Variables	Placebo group (n = 45)		Isoflavone group (n = 43)
	Baseline	Month 3	Baseline	Month 3
Endometrial histology					0.02
Normal	0	31 (68.9)	0	38 (88.4)
Hyperplasia	45 (100)	14 (31.1)	43 (100)	5 (11.6)
Estradiol (pg/ml)	89.1 ± 21.8	81.2 ± 20.8	85.2 ± 21.2	75.3 ± 19.6	0.26^†

Data are presented as a mean ± SD or numbers (%). Obtained from the chi-square test. ^†Obtained from the analysis of covariance (adjusted for the age and baseline estradiol value).